Insight Companies

Synovial Sarcoma Treatment Market Trends, Key Players and Growth Forecast

Synovial Sarcoma Treatment Market Overview

The synovial sarcoma treatment market was valued at USD 822.74 million in 2023 and is projected to grow to USD 1,144.84 million by 2033, with an estimated annual growth rate of 3.6% over the forecast period. Surgery continues to be the primary treatment method, holding a substantial 56% share of the market in 2023. North America leads the market, accounting for 41% of the total market share in 2023.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5121

Synovial sarcoma is a rare cancer that primarily affects young adults, usually under 30, and typically develops in the soft tissues around joints. Though it’s called “synovial” sarcoma, it doesn’t originate from the synovium. Early detection and treatment are vital, as it can spread quickly if untreated. Treatment often involves surgery, chemotherapy, and radiation.

The incidence of synovial sarcoma is rising, with about 800 to 1,000 cases annually. It’s caused by a chromosomal abnormality leading to fusion proteins that drive the cancer’s development.

New treatments are emerging, such as Catequentinib, which is being tested in a Phase 3 clinical trial. As the understanding of the disease grows, the demand for effective treatments is increasing.

Synovial Sarcoma Treatment Market Companies

  • Novartis: A global leader in healthcare, Novartis is known for its strong oncology portfolio, including targeted therapies and immunotherapies that may benefit patients with synovial sarcoma.
  • Eli Lilly and Company: Focused on advancing cancer treatments, Eli Lilly develops precision medicines and is exploring therapies that could target specific pathways involved in synovial sarcoma.
  • Adaptimmune: A pioneer in T-cell therapies, Adaptimmune leverages its expertise in engineered T-cell receptors (TCRs) to develop immunotherapies specifically aimed at synovial sarcoma, such as its SPEAR T-cell platform.
  • Takara Bio Inc.: Known for its innovative approaches to genetic and cellular therapies, Takara Bio develops products that have potential applications in treating synovial sarcoma and other solid tumors.
  • Johnson & Johnson: Through its Janssen Pharmaceutical division, Johnson & Johnson is focused on advancing oncology treatments, including immuno-oncology drugs and targeted therapies that could benefit synovial sarcoma patients.
  • F. Hoffmann-La Roche Ltd.: Roche is a global leader in cancer research and therapy development. Its targeted therapies and advancements in personalized medicine could provide new treatment options for synovial sarcoma.
  • Eisai Co., Ltd.: This Japanese pharmaceutical company is heavily invested in oncology, with research focused on precision medicine and new therapies targeting rare cancers, including synovial sarcoma.
  • Aadi Biosciences: Specializes in mTOR inhibitors, with a focus on rare cancers. Aadi Biosciences’ targeted therapies could offer innovative solutions for managing synovial sarcoma.
  • Immunocore Ltd.: A leader in T-cell receptor-based therapies, Immunocore develops cutting-edge immunotherapies that could address synovial sarcoma’s unique molecular profile.
  • GlaxoSmithKline (GSK): A major pharmaceutical company with a robust oncology pipeline, GSK is exploring therapies that harness the immune system to combat cancers like synovial sarcoma.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/synovial-sarcoma-treatment-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5121

We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

8 months ago
Elena Morales

Elena Morales is a healthcare industry expert working at Healthcare Web Wire Consulting Firm, a subsidiary of Towards Healthcare. With her excellent knowledge of the field, Elena helps clients optimize their operations and navigate healthcare regulations. She's dedicated to staying updated on industry trends to make a positive impact on patient care. Elena is known for her professionalism and commitment to excellence, making her a valuable asset to any team.

Leave a Comment

Related Post

Recent Posts

Kedrion Biopharma’s COAGADEX® Receives FDA Orphan Drug Designation for Acquired Factor X Deficiency (AFXD)

Kedrion Biopharma has announced that its human coagulation factor X concentrate, COAGADEX®, has been granted orphan drug designation by the… Read More

19 hours ago

Benecard PBF and DecisionRX Join Forces to Personalize and Optimize Pharmacy Benefits

enecard PBF, a pioneer in pharmacy benefit facilitation, has announced a strategic partnership with DecisionRX, Inc., a leader in medication… Read More

19 hours ago

Four Resilient Biotech Companies Making Waves in a Challenging Market

In a high-stakes biotech industry where drug development can span over a decade, four small but determined biotech companies are… Read More

19 hours ago

Natera Launches TEODOR Trial in Partnership with ABCSG to Advance Personalized Breast Cancer Treatment

cell-free DNA and precision medicine, has officially announced the launch of the TEODOR trial (ABCSG 61), a groundbreaking phase 2,… Read More

19 hours ago

Interventional Radiology Market: Size, Growth, and Leading Companies Driving Innovation

The global interventional radiology market is witnessing rapid expansion, driven by advancements in minimally invasive procedures, rising demand for diagnostic… Read More

24 hours ago

Physical Therapy Market Growth and Leading Companies Driving Innovation

The global physical therapy market is valued at USD 28.06 billion in 2024, growing to USD 29.18 billion in 2025… Read More

1 day ago

Connect with Us

Address: Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: USA - +1 650 460 3308

About Us

Contact Us

Annual Membership

Healthcare Web Wire is a premier subsidiary of Towards Healthcare, dedicated to providing comprehensive insights and information related to the healthcare industry. With a commitment to delivering accurate and timely updates, Healthcare Web Wire serves as a vital resource for professionals, enthusiasts, and stakeholders within the healthcare sector. Our platform serves as a central hub for the latest news, trends and developments shaping the healthcare landscape. Join us on Healthcare Web Wire and become part of a vibrant community dedicated to advancing healthcare knowledge and shaping the future of healthcare worldwide.

Address:
2nd Floor, Shreeleela Plaza, Baner Road, Pune, Maharashtra - 411045
sales@towardshealthcare.com
Contact:
+1 9197 992 333
+91 93077 85324

Gain access to the latest insights and statistics in the healthcare industry by subscribing to our Annual Membership. Stay updated on healthcare industry segmentation with detailed reports, market trends, and expert analysis tailored to your needs. Stay ahead of the curve with valuable resources and strategic recommendations. Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare: Get a Subscription